Illinois Cannabis Sales Fell to a Four-Year Low in 2025. Two Months Into 2026, They’re Already Worse.

For most of the last year, anyone trying to track Illinois cannabis sales data was flying blind. The state’s switch to the Metrc point-of-sale tracking system created a months-long reporting blackout, leaving operators, investors, and analysts without real numbers in one of the country’s most closely watched markets. The state finally released figures for January and February this week — catching up on two months of data at once.

What they show isn’t a market in recovery. It’s a market that contracted sharply in 2025 and is entering 2026 on a steeper downward slope.

The Numbers

Illinois adult-use cannabis sales totaled $1.51 billion in 2025. That’s a 12.5% decline from 2024’s $1.72 billion — and it puts the state below its 2022 total. After years of post-legalization expansion, including a 106% surge in 2021 and incremental gains through 2023, the market has now given back nearly all of those gains.

The 2026 early read is worse. January came in at $110.7 million, down 5.1% sequentially and 21.0% year-over-year. February was down another 5.4% month-over-month, though the year-over-year comparison improved slightly to -19.8% — in part because February 2025 was itself already weak. Two months into 2026, adult-use sales are down 20.4% on a year-over-year basis.

The medical program isn’t a counterweight. The last available medical data showed April 2025 sales of $19.7 million, down 1.6% sequentially and 13.2% year-over-year. There’s been no update since, meaning the picture on the medical side is at least as murky as adult-use was before this week’s data release.

What This Means for Operators

Illinois isn’t a peripheral market. It’s the home base for two of the industry’s largest multistate operators: Green Thumb Industries and Cresco Labs are both Chicago-headquartered companies with dense dispensary networks throughout the state. Curaleaf, Verano, Cannabist, and Ascend Wellness all carry meaningful Illinois exposure as well.

The timing is uncomfortable. Q4 2025 earnings reports are wrapping up across the sector, and the new data from Illinois lands just as those results are being digested. Seven of the largest MSOs reported Q4 revenue above $100 million — but the tracker maintained by New Cannabis Ventures notes that operating income was minimal or negative for most of them. Revenue scale without margin is a holding pattern, not a business model.

The 2026 consensus estimates that analysts were working with before this week look optimistic in light of the Illinois data. Curaleaf is expected to grow revenue 5% this year to roughly $1.33 billion; Green Thumb is forecast at 3% growth to $1.21 billion; Trulieve, Verano, and Cresco are all forecast flat to down. Those estimates were built on assumptions about market stabilization that a 20% YoY decline in Illinois’s first two months directly undermines — at least in this state.

None of the five largest MSOs have scheduled investor calls for their Q1 2026 results yet. Green Thumb has already said it won’t host a call at all.

The Metrc Problem Isn’t Just a Data Delay

The months-long data blackout caused by the Metrc switch deserves its own moment of examination. States invest significantly in compliance infrastructure on the premise that real-time tracking benefits operators, regulators, and the public alike. When that infrastructure fails to deliver usable data for quarters at a time, the market loses one of its few reliable signal sources.

Illinois operators were running their businesses without knowing what the state’s aggregate numbers looked like. Investors in publicly-traded MSOs couldn’t model Illinois contribution to revenue with any confidence. Analysts working on 2025 annual projections were guessing. All of that was a consequence of a system transition that the state knew would happen.

This isn’t a one-off. Several states have experienced extended data gaps around Metrc implementations or transitions between track-and-trace providers. The Illinois case is a useful reminder that compliance infrastructure can blind the market as easily as it can protect it.

The Structural Questions Illinois Can’t Answer Alone

The Illinois decline is significant, but it’s also part of a pattern. Whitney Economics projects that legal cannabis sales will return to growth nationally in 2026 after a rough 2025 — but the analysis also flags that falling prices, softening state performance, and a maturing market are reshaping what that growth actually looks like and who benefits from it.

The honest read is that large, well-capitalized MSOs are better positioned to weather a down market than the smaller operators who built many of these state markets from the ground up. But “better positioned” in the current environment means flat revenue at minimal margins, not growth. Illinois, which was supposed to be a long-term growth market with demographic and geographic scale, is right now acting like a market in contraction.

The reasons likely include persistent price compression, ongoing illicit-market competition, and possible consumer migration toward hemp-derived THC beverages — a product category that sits largely outside the regulated cannabis market. None of those pressures are unique to Illinois.

What is somewhat unique to Illinois is that until this week, nobody had real data to work with. Now they do. The picture it paints isn’t one that MSO investors should be comfortable with heading into Q1 2026 results season.

Caleb Quinn covers capital markets, MSO financials, and cannabis industry economics for CannabisInquirer.com. Reach him at caleb@cannabisinquirer.com.